Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

EARLY CLINICAL TESTING FOR MELANIN TARGETING RADIO-THERAPEUTIC AGENT IN MELANOMA

Award Number: R44CA141936
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/25/2009
PERIOD OF PERFORMANCE END DATE: 10/31/2011

Group Awards By:

View Award Description

EARLY CLINICAL TESTING FOR MELANIN TARGETING RADIO-THERAPEUTIC AGENT IN MELANOMA - DESCRIPTION (provided by applicant): The ultimate goal of this Fast Track Phase I/II SBIR proposal is to perform the clinical assessment of a novel pharmaceutical agent, ioflubenzamide I-131, to evaluate its potential as a molecular targeting radio-therapeutic treatment for metastatic melanoma. Preliminary results in melanin expressing cell cultures, demonstrate high and selective binding to melanoma cancers. Organ distribution studies in mouse tumor models showed high accumulation in tumors and rapid elimination through the renal and hepatobillary systems. Early human testing, of a similar compound in this series, also demonstrated high uptake and retention in tumors of metastatic melanoma patients. However, process development studies of this earlier lead compound indicated it was too unstable to scale up to high radioactive concentrations. Ioflubenzamide I-131 is a radio-iodinated benzamide molecule with extremely high selective binding to melanin expressing melanomas and low non-target organ accumulation. The molecular target specificity, high tumor accumulation and retention are ideal properties for an agent to effectively treat melanoma metastasis. Preliminary preclinical efficacy studies demonstrated complete tumor remission after two treatments (0.68 mCi) with ioflubenzamide I-131 in a SK-Mel-3 human melanoma xenograft mouse model (about 100 mCi/m2 as a human dose equivalent). The first six month phase of this proposal will focus on generating CMC documentation necessary to support an exploratory IND application to the FDA. The second phase of the proposal will be initiated after the protocol has been accepted by the FDA. This 18 month phase 2 portion will focus on executing and completing a clinical imaging study in 12 (male and female) subjects with confirmed metastatic malignant melanoma to determine safety and organ dosimetry. The justification for requesting Fast Track consideration is to establish the proof-of-principal and select a therapeutic starting dose for a therapy escalation study. The innovation in this proposal is the exciting promise for a potential curative treatment of metastatic melanoma. Following successful completion of the SBIR program, Molecular Insight will develop a clinic protocol to determine dosage and efficacy for an industry sponsored NDA to the FDA. PUBLIC HEALTH RELEVANCE: The incidence of malignant melanoma is rising faster than that of any other types of cancer in the United States. A radiopharmaceutical, capable of being labeled with cell destroying radioisotopes and exclusively targeted to melanoma tissue, would provide a drug specific for the treatment of metastatic disease. The successful development of an I-131 labeled molecular targeting radiotherapeutic agent for malignant melanoma would introduce this therapeutic technique to a now incurable disease and bring considerable attention to the field of therapeutic radiology. Molecular Insights desires to test a new molecular targeting agent: ioflubenzamide I-131 in subjects with confirmed melanin positive metastatic melanomas, to determine its potential as a systemic radiotherapy agent. The rising incidence of malignant melanomas, the early and wide-spread occurrence of metastases, and the poor response rates for current therapies, creates an essential need and valuable commercial opportunity to effectively treat patients with metastatic melanomas.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2012 ( Subtotal = $0 )
2012	2011	MOLECULAR INSIGHT PHARMACEUTICALS INC	160 SECOND STREET	CAMBRIDGE	MA	02142	MIDDLESEX	USA	Cancer Treatment Research	000	3	1/4/2012	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2011 ( Subtotal = $737,540 )
2011	2011	MOLECULAR INSIGHT PHARMACEUTICALS INC	160 SECOND STREET	CAMBRIDGE	MA	02142	MIDDLESEX	USA	Cancer Treatment Research	000	3	7/22/2011	NON-COMPETING CONTINUATION	$737,540
														Subtotal = $737,540

Issue Date FY: 2010 ( Subtotal = $559,294 )
2010	2010	MOLECULAR INSIGHT PHARMACEUTICALS INC	160 SECOND STREET	CAMBRIDGE	MA	02142	MIDDLESEX	USA	Cancer Treatment Research	000	2	6/11/2010	EXTENSION WITH OR WITHOUT FUNDS	$559,294
														Subtotal = $559,294

Issue Date FY: 2009 ( Subtotal = $223,985 )
2009	2009	MOLECULAR INSIGHT PHARMACEUTICALS INC	160 SECOND STREET	CAMBRIDGE	MA	02142	MIDDLESEX	USA	Cancer Treatment Research	000	1	6/17/2009	NEW	$223,985
														Subtotal = $223,985

Grand Total All Awards = $1,520,819

Top

All Categories

About

Search

Reports

Data Submission

Award Information

EARLY CLINICAL TESTING FOR MELANIN TARGETING RADIO-THERAPEUTIC AGENT IN MELANOMA

Award Number: R44CA141936

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/25/2009

PERIOD OF PERFORMANCE END DATE: 10/31/2011

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer